

pathogen, is exposed to the host immune system on the surface of free pathogen and/or pathogen-infected cells.--

¹⁰ ~~--11~~. A composition in accordance with Claim ¹~~10~~ wherein the microspheres further contain a pharmaceutically-acceptable adjuvant.--

³ ~~--12~~. The immunostimulating compositions described in claims 1 or 2 wherein the immunogenic substance is a native (oligomeric) HIV-1 envelope antigen that is conformationally stabilized by the polymer matrix and serves to elicit in animals the production of HIV specific cytotoxic T lymphocytes and antibodies preferentially reactive against native HIV-1 envelope antigen.--

[(Additionally, please add the following claims.)

¹¹
^{cont}
¹²
¹³ ~~--Claim 13~~. A vaccine consisting of a blend of the immunostimulating compositions described in Claims 5 and 6.--

¹³
~~--Claim 14~~. The immunostimulating compositions described in claim 6 employed as a parentally administered vaccine wherein the diameter size range of said vaccine microspheres lies between 1 nanometer and 20 microns.--

¹³
~~--Claim 15~~. The immunostimulating compositions described in claim 7 employed as a parentally administered vaccine wherein the diameter size range of said vaccine microspheres lies between 1 nanometer and 20 microns.--

¹⁴
~~--Claim 16~~. The immunostimulating compositions described in claim 6 employed as a mucosal vaccine wherein the size of more than 50% (by volume) of said vaccine microspheres is between 5 to 10 microns in diameter.

In Claim 2, line 1, replace "Claim #1" with --Claim 1--;

16